In-vitro-activity of Piperacillin/Sulbactam and Piperacillin/Tazobactam;In-vitro-aktivität von Piperacillin/Sulbactam und Piperacillin/Tazobactam: Vergleich bei klinisch relevanten bakteriellen infektionserregern

Chemotherapie Journal

Volumn 10, Issue 5, 2001, Pages 181-187

  Rodloff, A C ^a   Pless B ^a   Beer, J ^a   Spencker, F B ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Local epidemiology; MIC distributions; Piperacillin Sulbactam; Piperacillin Tazobactam

Indexed keywords

AMPICILLIN; BETA LACTAMASE; CEFOPERAZONE; MEZLOCILLIN; PIPERACILLIN; SULBACTAM; TAZOBACTAM;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; DILUTION; DRUG POTENCY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS;

EID: 18144438097     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. A functional classification scheme for β-lactamases and its correlation with molecular structure
2. Genars projekt etabliert
3. Resistenzsituation bei klinisch wichtigen Infektionserregem gegenUΣber Chemotherapeutika in Mitteleuropa
4. Importance of β-lactamase inhibitor pharmacokinetics in pharmacodynamics of inhibitor-drug combinations: Studies with piperacillin-tazobactam and piperacillin-sulbactam
5. Pharmacokinetic properties of beta-lactamase inhibitors
6. Nicht nur ESBL produzierende E.-coli-stämme bereiten therapeutische probleme - Ein fallbericht
7. The epidemiology of beta-lactamases
8. Beta-Lactamasen und beta-lactamase-inhibitoren